Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.
1. A method for monitoring the effectiveness of cyclobenzaprine treatment for disordered sleep in a subject at risk of suffering from disordered sleep, who has received the cyclobenzaprine treatment, the method comprising:
a) measuring the CAP A1, A2 and A3 rates in the subject;
b) generating an nCAP A2+A3 (CAP A2+A3(Norm) ) value from the measurements in a); and
c) monitoring the effectiveness of the cyclobenzaprine treatment for disordered sleep wherein the cyclobenzaprine treatment is effective when the CAP A2+A3(Norm) value generated in step b) is less than or equal to a threshold CAP A2+A3(Norm) value generated in subjects suffering from disordered sleep who have received a placebo.
2. The method of claim 1 , wherein the specified CAP A2+A3(Norm) threshold value is ≦33%.